EUVIMEDEUVIMED entdecken
Crossref

Leflunomide‐inhibited STAT1 activity ameliorates intramuscular M1 macrophage infiltration and promotes muscle regeneration in Duchenne muscular dystrophy

Wanting Hu iD, Haowei Tong iD, Maolin Zhu, Huna Wang, Xiaofei Huang, Shusheng Fan iD, Guangyao Guo, Mohammed Ismail, Lei Zhao iD, Xihua Li, Luyong Zhang iD, Qinwei Yu iD und 1 weitere

British Journal of Pharmacology · 2026-09 · 183 (18) · 5496-5515

DOI: 10.1111/bph.70518 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 26.06.2026. Verfasst von Wanting Hu und 12 weiteren Autor:innen. Beteiligte Einrichtung: New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, STAT1 Transcription Factor, Macrophages, Leflunomide. Die Arbeit nennt 93 Literaturangaben. Gefördert von: Postgraduate Research Practice Innovation Program of Jiangsu Province, National Key Research and Development Program of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Duchenne muscular dystrophy (DMD) is an X‐linked recessive disorder caused by dystrophin gene mutations. This study investigated the therapeutic effects of leflunomide, a STAT1 inhibitor on dystrophic muscles. Experimental Design The characterization of M1 macrophage polarization and the level of STAT1/ p ‐STAT1 were measured in DMD patients. Lipopolysaccharide (LPS)/IFN‐γ and RO8191 were selected to stimulate STAT1 for evaluating the inhibitory effect of A771726 on M1 polarization and STAT1. Conditionally cocultured M1 RAW264.7 cells and differentiated C2C12 myoblasts were used to explore the differentiation of A771726 to myopathy in inflammatory environments. After 4‐week treatment with leflunomide, the protein levels of STAT1 and p ‐STAT1 were evaluated in mdx mice. CD86 and CD68 were selected for evaluating inflammation event. The proinflammatory cytokines were measured by RT‐PCR and ELISA. Muscle function and myofibre damage were examined by behavioural experiments and serum CK and LDH level, respectively. The muscle regeneration event was demonstrated by myosin heavy chain, myogenic differentiation (MyOD) protein levels and eMyHC immunofluorescence. Key Results STAT1 was remarkably upregulated in mdx mice and DMD patients compared with control groups. A771726 restrained LPS/IFN‐γ‐induced M1 macrophage polarization via inhibiting p ‐STAT1 and STAT1. Specific activation of STAT1 by RO8191 promoted macrophage polarize towards M1 type, which was partially counteracted by A771726. Leflunomide‐inhibited inflammation infiltration mediated by M1 macrophage and exerted promising therapeutic effect on muscle repair in mdx mice. Conclusions and Implications Leflunomide relieved M1 macrophage infiltration and improved muscle regeneration by downregulating STAT1 and p ‐STAT1. STAT1 may merge as a promising target for the therapy of DMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneSTAT1 Transcription FactorMacrophagesLeflunomideRegenerationMuscle, SkeletalAnimalsMiceMice, Inbred mdxHumansMaleMice, Inbred C57BLRAW 264.7 Cells

Stichwörter der Autor:innen

Duchenne muscular dystrophyintramuscular inflammationleflunomidemuscle regenerationsignal transducer and activator of transcription 1

Substanzen

STAT1 Transcription FactorLeflunomideStat1 protein, mouseSTAT1 protein, human

Autor:innen und Institutionen

  • New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
  • Department of Neurology, Children's Hospital of Fudan University, Shanghai, China.
  • Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, China.
  • Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, Nanjing, China.
  • Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, Nanjing, China.

ORCID-Profile: Wanting Hu, Haowei Tong, Shusheng Fan, Lei Zhao, Luyong Zhang, Qinwei Yu, Zhenzhou Jiang

Förderung

  • Postgraduate Research Practice Innovation Program of Jiangsu Province
  • National Key Research and Development Program of China
  • China Postdoctoral Science Foundation
  • Experimental Animal Association Research Project Contract
  • National Basic Research Program of China

Zitieren

APA

Hu, W., Tong, H., Zhu, M., Wang, H., Huang, X., Fan, S., Guo, G., Ismail, M., Zhao, L., Li, X., Zhang, L., Yu, Q., & Jiang, Z. (2026). Leflunomide‐inhibited STAT1 activity ameliorates intramuscular M1 macrophage infiltration and promotes muscle regeneration in Duchenne muscular dystrophy. British Journal of Pharmacology, 183(18), 5496-5515. https://doi.org/10.1111/bph.70518

Vancouver

Hu W, Tong H, Zhu M, Wang H, Huang X, Fan S, et al. Leflunomide‐inhibited STAT1 activity ameliorates intramuscular M1 macrophage infiltration and promotes muscle regeneration in Duchenne muscular dystrophy. British Journal of Pharmacology. 2026;183(18):5496-5515. doi:10.1111/bph.70518

BibTeX
@article{Hu2026,
  author = {Hu, Wanting and Tong, Haowei and Zhu, Maolin and Wang, Huna and Huang, Xiaofei and Fan, Shusheng and Guo, Guangyao and Ismail, Mohammed and Zhao, Lei and Li, Xihua and Zhang, Luyong and Yu, Qinwei and Jiang, Zhenzhou},
  title = {Leflunomide‐inhibited STAT1 activity ameliorates intramuscular M1 macrophage infiltration and promotes muscle regeneration in Duchenne muscular dystrophy},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {18},
  pages = {5496--5515},
  doi = {10.1111/bph.70518}
}
Kostenlos starten →